16 Apr, 2019 12:43 PM
SYDNEY, Australia, 16 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce its Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 Marc...read more
12 Apr, 2019 09:30 AM
Integrated Payment Technologies Limited (ASX:IP1) (InPayTech) is pleased to announce the completion of the institutional component (Institutional Entitlement Offer) announced on Wednesday, 10 April 20...read more
03 Apr, 2019 08:22 AM
SYDNEY, Australia, 3 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, together with the Medical University Vienna today presented positive new data on the PD-1 mimotope...read more
02 Apr, 2019 06:29 PM
Eftilagimod Alpha Clinical Development Update and New Data from Ongoing Melanoma Study
Date & Time:
Wednesday, April 3, 2019, 7:45am Australian Eastern Standard Time
Tuesday, April 2, 2019,...read more
02 Apr, 2019 09:56 AM
SYDNEY, Australia, 2 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic presented new data on the KEY-Vaxx and ...read more
02 Apr, 2019 08:14 AM
SYDNEY, Australia, 2 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase Ib study of its HER-Vaxx cancer vaccine at the American Asso...read more
27 Mar, 2019 05:29 PM
SYDNEY, AUSTRALIA – March 27, 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy trea...read more
25 Mar, 2019 07:28 PM
Date & Time: March 26, 2019, 7:45 am Australian Eastern Daylight Time March 25, 2019, 4:45 pm US Eastern Daylight Time
The LAG-3 Agonist Concept
IMP761: In Vitro Testing
IMP761: In Vivo T...read more
22 Mar, 2019 07:22 AM
SYDNEY, AUSTRALIA – 22 March 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treat...read more
20 Mar, 2019 10:11 AM
Sydney, Australia, 20 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND...read more
19 Mar, 2019 10:02 AM
Immutep to Present IMP761 Preclinical Results in Global Webcast
SYDNEY, AUSTRALIA – March 19, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company...read more
